Form D
View Original Filing
Notice of Exempt Offering of Securities
Item 1. Issuer's Identity
Name of Issuer:
INNOVATE BIOPHARMACEUTICALS, INC.
Jurisdiction of Incorporation/Organization
DELAWARE
Year of Incorporation/Organization
Over Five Years Ago
Previous Name(s)
- MONSTER DIGITAL, INC.
- TANDON DIGITAL, INC.
Item 2 Issuer Principal Place of Business and Contact Information
8480 HONEYCUTT ROAD
SUITE 120
RALEIGH, NC 27615
Phone Number:
subscription required
Item 3. Related Persons
Name
SANDEEP LAUMAS
Address
subscription required
Relationship(s)
- EXECUTIVE OFFICER
- DIRECTOR
Clarification of Response
Item 3. Related Persons
Name
JAY MADAN
Address
subscription required
Relationship(s)
- EXECUTIVE OFFICER
- DIRECTOR
Clarification of Response
Item 3. Related Persons
Name
ANTHONY MAIDA
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
LORIN JOHNSON
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
SAIRA RAMASASTRY
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
ROY PROUJANSKY
Address
subscription required
Relationship(s)
Clarification of Response
Item 4. Industry Group
PHARMACEUTICALS
Item 5. Issuer Size
Revenue Range (for issuer not specifying "hedge" or "other investment" fund in Item 4 above)
DECLINE TO DISCLOSE
Item 6. Federal Exemptions and Exclusions Claimed
Item 7. Type of Filing
New Notice
Date of First Sale in this Offering:
03/08/2019
Item 8. Duration of Offering
Does the issuer intend this offering to last more than one year?
No
Item 9. Type(s) of Securities Offered
Item 10. Business Combination Transaction
Is this offering being made in connection with a business combination
transaction, such as a merger, acquisition or exchange offer?
No
Clarification of Response
Item 11. Minimum Investment
Minimum Investment accepted from any outside investor
0
Item 13. Offering and Sales Amounts
Total Offering Amount
5500000
Total Amount Sold
5500000
Total Remaining to be Sold
0
Clarification of Response
Item 14. Investors
Securities in the offering have been or may be sold to persons
who do not qualify as accredited investors,
Number of non-accredited investors who already have invested in the offering:
Total number of investors who already have invested in the offering:
1
Item 15. Sales Commissions and Finders' Fees Expenses
Sales Commissions:
0.0
Finders' Fees
0.0
Clarification of Response
Item 16. Use of Proceeds
Provide the amount of the gross proceeds of the offering
that has been or is proposed to be used for payments to any of the persons required
to be named as executive officers,directors or promoters in response to Item 3 above.
0.0
Clarification of Response
NONE OTHER THAN PAYMENTS OF SALARY IN THE ORDINARY COURSE OF BUSINESS.
Signature and Submission
Issuer Name
INNOVATE BIOPHARMACEUTICALS, INC.
Issuer Signature
/S/ JAY MADAN
Signer Name
JAY MADAN
Signer Title
CHIEF BUSINESS OFFICER
Signature Date
03/15/2019